For instance, the use of the FXR antagonist glycine-β-muricholic acid, that inhibits FXR signalling exclusively in the intestine, was proposed to improve the metabolic parameters in mouse models of obesity through an intestinal FXR–ceramide axis [22]. This evidence concerns the gene NR1H4 and obesity disorder.